LABT (Lakewood-Amedex Biotherapeutics) Debt-to-Equity: -0.62 (As of Mar. 2026)


LABT Lakewood-Amedex Biotherapeutics Inc LABT
8 GF Score
Price $3.55
View Full Analysis

What is Lakewood-Amedex Biotherapeutics Debt-to-Equity?

Lakewood-Amedex Biotherapeutics LABT +2.33% 8 Debt-to-Equity is -0.62 as of Mar. 2026. GuruFocus rates LABT with a GF Score™ of 8/100. Among 968 Biotechnology companies, Lakewood-Amedex Biotherapeutics ranks worse than 103305.68% on this metric.

Lakewood-Amedex Biotherapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $1.75 Mil. Lakewood-Amedex Biotherapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $0.01 Mil. Lakewood-Amedex Biotherapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $-2.84 Mil. Lakewood-Amedex Biotherapeutics's debt to equity for the quarter that ended in Mar. 2026 was -0.62.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Lakewood-Amedex Biotherapeutics's Debt-to-Equity or its related term are showing as below:

LABT' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.33   Med: -0.62   Max: 0.67
Current: -0.62

During the past 3 years, the highest Debt-to-Equity Ratio of Lakewood-Amedex Biotherapeutics was 0.67. The lowest was -1.33. And the median was -0.62.

LABT's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.16 vs LABT: -0.62

Lakewood-Amedex Biotherapeutics  (NAS:LABT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Lakewood-Amedex Biotherapeutics Debt-to-Equity Related Terms

Lakewood-Amedex Biotherapeutics Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Lakewood-Amedex Biotherapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lakewood-Amedex Biotherapeutics Debt-to-Equity Chart

Lakewood-Amedex Biotherapeutics Annual Data
Trend Dec23 Dec24 Dec25
Debt-to-Equity
0.13 0.67 -0.85

Lakewood-Amedex Biotherapeutics Quarterly Data
Dec23 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Debt-to-Equity Get a 7-Day Free Trial 0.67 N/A -1.33 -0.85 -0.62

LABT vs CURX, PBM, NCNA: Debt-to-Equity Comparison

For the Biotechnology subindustry, Lakewood-Amedex Biotherapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lakewood-Amedex Biotherapeutics Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lakewood-Amedex Biotherapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Lakewood-Amedex Biotherapeutics's Debt-to-Equity falls into.


LABT
8GF Score
Lakewood-Amedex Biotherapeutics Inc LABT
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lakewood-Amedex Biotherapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Lakewood-Amedex Biotherapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(1.619 + 0.041) / -1.965
=-0.84

Lakewood-Amedex Biotherapeutics's Debt to Equity Ratio for the quarter that ended in Mar. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(1.746 + 0.01) / -2.842
=-0.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -0.62 mean?
Lakewood-Amedex Biotherapeutics (LABT) has a Debt-to-Equity of -0.62 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Lakewood-Amedex Biotherapeutics and its competitors. According to the industry distribution chart, Lakewood-Amedex Biotherapeutics ranks #999999 out of 968 companies in the Biotechnology industry.
Is Lakewood-Amedex Biotherapeutics' Debt-to-Equity too high?
Lakewood-Amedex Biotherapeutics' current Debt-to-Equity is -0.62. Based on the distribution chart, Lakewood-Amedex Biotherapeutics ranks #999999 out of 968 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lakewood-Amedex Biotherapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Lakewood-Amedex Biotherapeutics' Debt-to-Equity compare to CURX and PBM?
According to the Biotechnology industry distribution chart, Lakewood-Amedex Biotherapeutics ranks #999999 out of 968 companies for Debt-to-Equity. This places Lakewood-Amedex Biotherapeutics in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 968 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Lakewood-Amedex Biotherapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lakewood-Amedex Biotherapeutics's current Debt-to-Equity is -0.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakewood-Amedex Biotherapeutics stock overvalued right now?
Lakewood-Amedex Biotherapeutics (LABT) has a current Debt-to-Equity of -0.62. The current Debt-to-Equity is -0.62. Lakewood-Amedex Biotherapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Lakewood-Amedex Biotherapeutics (LABT), the current Debt-to-Equity is -0.62 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lakewood-Amedex Biotherapeutics Business Description

Address 8031 Cooper Creek Blvd, Unit 103, University Park, FL, USA, 34201
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
8GF Score

Get the complete analysis for LABT

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.55
Price